Onco-Innovations (STU:W1H) Other Current Receivables: €0.02 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:W1H Onco-Innovations Ltd STU:W1H
12 GF Score
Price €0.33
! 2 Warning Signs
View Full Analysis

What is Onco-Innovations Other Current Receivables?

Onco-Innovations STU:W1H -2.79% 12 Other Current Receivables is €0.02 Mil as of Apr. 2026. GuruFocus rates STU:W1H with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Onco-Innovations's Other Current Receivables for the quarter that ended in Apr. 2026 was €0.02 Mil.

Onco-Innovations's quarterly Other Current Receivables declined from Oct. 2025 (€0.06 Mil) to Jan. 2026 (€0.02 Mil) but then increased from Jan. 2026 (€0.02 Mil) to Apr. 2026 (€0.02 Mil).

Onco-Innovations's annual Other Current Receivables increased from Apr. 2024 (€0.00 Mil) to Apr. 2025 (€0.03 Mil) but then declined from Apr. 2025 (€0.03 Mil) to Apr. 2026 (€0.02 Mil).

Onco-Innovations Other Current Receivables Related Terms

Onco-Innovations Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Onco-Innovations's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onco-Innovations Other Current Receivables Chart

Onco-Innovations Annual Data
Trend Apr23 Apr24 Apr25 Apr26
Other Current Receivables
0.00 0.00 0.03 0.02

Onco-Innovations Quarterly Data
Apr23 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.05 0.06 0.02 0.02
STU:W1H
12GF Score
Onco-Innovations Ltd STU:W1H
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onco-Innovations Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.02 Mil mean?
Onco-Innovations (STU:W1H) has a Other Current Receivables of €0.02 Mil as of Apr. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Onco-Innovations and its competitors.
Is Onco-Innovations' Other Current Receivables too high?
Onco-Innovations' current Other Current Receivables is €0.02 Mil. Overall, Onco-Innovations has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Onco-Innovations' Other Current Receivables compare to VRTX and REGN?
Onco-Innovations' Other Current Receivables of €0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Onco-Innovations and its competitors. Onco-Innovations's current Other Current Receivables is €0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onco-Innovations stock overvalued right now?
Onco-Innovations (STU:W1H) has a current Other Current Receivables of €0.02 Mil. The current Other Current Receivables is €0.02 Mil. Onco-Innovations' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Onco-Innovations (STU:W1H), the current Other Current Receivables is €0.02 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Onco-Innovations Business Description

Other Exchanges ONCO:Canada
Address 7th Street South West, Suite 1039, Calgary, AB, CAN, T2R 1A5
Onco-Innovations Ltd is a pre-clinical stage biotechnology company working on developing drug candidates that can increase the effectiveness of current cancer treatments.
12GF Score

Get the complete analysis for STU:W1H

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.33
Price